Your session is about to expire
← Back to Search
Amino Acid
Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis (ALS) (ALS Trial)
Phase 2
Waitlist Available
Led By Elijah W Stommel, MD,PHD
Research Sponsored by Elijah W. Stommel
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 1 year
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing if taking L-Serine by mouth is safe for people with ALS and if it might help them. All participants will take the same dose for several months. The study will last about a year, including follow-up visits to check their health. L-Serine has been previously tested for ALS patients, focusing on safety.
Eligible Conditions
- ALS
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline, 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 1 year
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Dose tolerability based on subject reporting
Secondary study objectives
Efficacy based on ALS Functional Rating Scale - Revised (ALSFRS-R)
Efficacy based on neurological exam
Efficacy based on pulmonary forced vital capacity
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: L-SerineExperimental Treatment1 Intervention
L-Serine 15 grams orally twice a day as tolerated for 6 months
Find a Location
Who is running the clinical trial?
Elijah W. StommelLead Sponsor
Brain Chemistry Labs, Institute for EthnomedicineUNKNOWN
1 Previous Clinical Trials
29 Total Patients Enrolled
Elijah W Stommel, MD,PHDPrincipal InvestigatorDartmouth-Htichcock Medical Center